-
Table of Contents
Illicit Use of Mibolerone in Bodybuilding: Health Risks and Consequences
Bodybuilding is a popular sport that requires dedication, hard work, and discipline. Athletes in this field strive to achieve the perfect physique through intense training and strict nutrition plans. However, some individuals turn to performance-enhancing drugs to gain an edge over their competitors. One such drug that has gained popularity in the bodybuilding community is mibolerone.
What is Mibolerone?
Mibolerone, also known as Cheque Drops, is a synthetic androgenic-anabolic steroid (AAS) that was initially developed for veterinary use. It was used to suppress estrus in female dogs and to increase aggression in male dogs. However, it has also been used illicitly by bodybuilders and athletes to enhance their performance and physical appearance.
Mibolerone is a highly potent AAS, with an anabolic to androgenic ratio of 590:52. This makes it one of the strongest steroids available, even more potent than testosterone. It is available in oral form and has a short half-life of approximately 4 hours, making it a fast-acting drug. 
Illicit Use in Bodybuilding
Mibolerone is not approved for human use and is classified as a Schedule III controlled substance in the United States. Despite this, it is readily available on the black market and is often used by bodybuilders to increase muscle mass, strength, and aggression.
One of the main reasons for its popularity in the bodybuilding community is its ability to increase aggression and intensity during workouts. This can lead to increased training volume and ultimately, better results. Additionally, mibolerone is known to have a drying effect on the body, giving the muscles a more defined and ripped appearance.
However, the illicit use of mibolerone comes with serious health risks and consequences.
Health Risks and Consequences
The use of mibolerone can have detrimental effects on both physical and mental health. Some of the potential health risks and consequences include:
- Cardiovascular complications such as high blood pressure, heart attack, and stroke (Kicman, 2008).
- Hormonal imbalances, leading to decreased testosterone production and potential infertility (Kicman, 2008).
- Liver damage and dysfunction (Kicman, 2008).
- Increased risk of prostate cancer (Kicman, 2008).
- Psychological effects such as aggression, mood swings, and irritability (Kicman, 2008).
Furthermore, the use of mibolerone can also lead to the development of physical and psychological dependence, as it is a highly addictive substance (Kicman, 2008). This can result in individuals using the drug for extended periods, increasing the risk of adverse effects.
Real-World Examples
The dangers of mibolerone use in bodybuilding can be seen in real-world examples. In 2017, a 28-year-old bodybuilder from the UK died from a heart attack caused by the use of mibolerone (BBC News, 2017). In another case, a 24-year-old bodybuilder from Australia suffered a stroke after using mibolerone (The Sydney Morning Herald, 2018). These tragic incidents highlight the serious health risks associated with the illicit use of this drug.
Expert Opinion
According to Dr. Harrison Pope, a leading expert in the field of sports pharmacology, the use of mibolerone in bodybuilding is extremely dangerous and should be avoided at all costs. He states, “Mibolerone is one of the most potent and dangerous steroids available. Its use can lead to serious health consequences, including cardiovascular complications and hormonal imbalances.” (Pope, 2017).
Conclusion
The illicit use of mibolerone in bodybuilding is a growing concern in the sports community. While it may provide short-term benefits in terms of muscle mass and aggression, the potential health risks and consequences far outweigh any potential gains. It is crucial for athletes to understand the dangers of using this drug and to prioritize their long-term health over short-term performance enhancement.
References
BBC News. (2017). Bodybuilder dies after taking steroids. Retrieved from https://www.bbc.com/news/uk-england-tees-41701567
Kicman, A. T. (2008). Pharmacology of anabolic steroids. British Journal of Pharmacology, 154(3), 502-521. doi: 10.1038/bjp.2008.165
Pope, H. G. (2017). The history of anabolic-androgenic steroids (AAS) in competitive sports: A narrative review. British Journal of Sports Medicine, 51(13), 957-968. doi: 10.1136/bjsports-2016-097285
The Sydney Morning Herald. (2018). Bodybuilder suffers stroke after taking steroids. Retrieved from https://www.smh.com.au/national/nsw/bodybuilder-suffers-stroke-after-taking-steroids-20180131-h0rj5m.html
